The global Allogeneic Cell Therapy Market is set to increase at a compound annual growth rate of 12.7% throughout the 2023–2031 forecast period.
The Allogeneic Cell Therapy sector involves key industry insights & findings from the report:
Enhancements in cell engineering and manufacturing processes are making allogenic cell therapies more accessible and effective. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is fueled by expanding requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2.Executive Summary
Chapter 3.Global Allogeneic Cell Therapy Market Snapshot
Chapter 4.Global Allogeneic Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5.Market Segmentation 1: By Type of Cell Therapy Estimates & Trend Analysis
5.1. By Type of Cell Therapy & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Type of Cell Therapy:
5.2.1. Virus-Specific T-Cell
5.2.2. Stem Cell
5.2.3. Regulatory T-Cell
Chapter 6.Market Segmentation 2: By Source of Cell Estimates & Trend Analysis
6.1. By Source of Cell & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Source of Cell:
6.2.1. Peripheral Blood
6.2.2. Bone Marrow
6.2.3. Umbilical Cord Blood
6.2.4. Adipose Tissue
6.2.5. Placenta
Chapter 7.Market Segmentation 3: By Target Indication Estimates & Trend Analysis
7.1. By Target Indication & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Target Indication:
7.2.1. Bone Disorder
7.2.2. Critical Limb Ischemia
7.2.3. Crohn's Disease
7.2.4. Diabetic Foot Ulcer
7.2.5. Graft versus Host Disease
7.2.6. Leukemia
7.2.7. Lymphoma
7.2.8. Myelodysplastic Syndrome
7.2.9. Cytomegalovirus Infection
7.2.10. Others
Chapter 8.Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
8.1. By Therapeutic Area & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Type By Therapeutic Area:
8.2.1. Oncological Disorders
8.2.2. Neurological Disorders
8.2.3. Musculoskeletal Disorder
8.2.4. Autoimmune / Inflammatory Disorders
8.2.5. Post-Transplant Infections
Chapter 9.Allogeneic Cell Therapy Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Type of Cell Therapy, 2023-2031
9.1.2. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.1.3. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.1.4. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.1.5. North America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.2.2. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.2.3. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.2.4. Europe Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.2.5. Europe Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2023-2031
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.3.2. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.3.3. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.3.4. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.3.5. Asia Pacific Allogeneic Cell Therapy Market revenue (US$ Million) by country, 2023-2031
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, 2023-2031
9.4.2. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.4.3. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.4.4. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.4.5. Latin America Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by By Type of Cell Therapy, (US$ Million)
9.5.2. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Source of Cell, 2023-2031
9.5.3. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Indication, 2023-2031
9.5.4. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2023-2031
9.5.5. Middle East & Africa Allogeneic Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10.Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. TCR² Therapeutics
10.2.2. TiGenix (Takeda)
10.2.3. Adaptimmune Therapeutics plc,
10.2.4. Adicet Bio, Inc.,
10.2.5. Allogene Therapeutics,
10.2.6. Allogene Therapeutics,
10.2.7. Artiva Biotherapeutic,
10.2.8. Atara Biotherapeutics,
10.2.9. Athersys, Inc.,
10.2.10. BioCardia Inc.,
10.2.11. Bluebird Bio,
10.2.12. BlueRock Therapeutics LP,
10.2.13. Bone Therapeutics,
10.2.14. Capricor Therapeutics,
10.2.15. Cell2Cure,
10.2.16. Cellectis,
10.2.17. Cellenkos,
10.2.18. Cellular Biomedicine Group,
10.2.19. Celularity,
10.2.20. Celyad,
10.2.21. Century Therapeutics,
10.2.22. CHABiotech,
10.2.23. CRISPR Therapeutics,
10.2.24. Cynata Therapeutics,
10.2.25. Cyto Therapeutics Pty Limited,
10.2.26. Fate Therapeutics,
10.2.27. Fate Therapeutics,
10.2.28. Fundamenta Therapeutics,
10.2.29. GammaDelta Therapeutics Limited,
10.2.30. GC Cell,
10.2.31. Hope Biosciences,
10.2.32. Immunity Bio,
10.2.33. Lineage Cell Therapeutics, Inc.,
10.2.34. MEDIPOST,
10.2.35. Mesoblast Ltd,
10.2.36. Nanjing Bioheng Biotech,
10.2.37. NantKwest,
10.2.38. Nkarta, Inc.,
10.2.39. Orca Bio,
10.2.40. Organogenesis Inc.,
10.2.41. Osiris Therapeutics, Inc.,
10.2.42. Pluristem Therapeutics Inc,
10.2.43. Poseida Therapeutics
10.2.44. Regeneus,
10.2.45. Stemedica Cell Technologies, Inc.,
10.2.46. Stempeutics